title: CHOP Chemotherapy Followed by Tositumomab and Iodine-131 Tositumomab for Previously Untreated Diffuse Large B-cell Lymphoma.
abstract: The efficacy and safety of tositumomab/iodine-131 tositumomab (TST/I-131 TST) were evaluated in diffuse large B-cell lymphoma patients who responded to first-line cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP). Fifteen patients (median age, 52 years) received dosimetric and therapeutic doses of TST/I-131 TST. The most common Grade 3/4 hematologic adverse events were decreased absolute neutrophil count (47%), white blood cell count (40%), platelet count (27%), and hemoglobin (20%). The complete response (CR) rate increased from 60% post-CHOP to 80% post TST / I-131 TST. With a median follow-up of 120.0 months (range, 14-130 months), median duration of response (95% confidence intervals) was 58.4 months (12.0-not reached [NR]) for patients with confirmed complete response and 58.4 months (20.9-NR) for all confirmed responders. Median progression-free survival and time to treatment failure were 63.0 months (16.1-NR). Median overall survival was not reached; 2 patients died on study. CHOP and TST/I-131 TST demonstrated clinical activity with acceptable toxicity.
authors.affiliation: Weill Cornell Medical College and New York Presbyterian Hospital, New York, NY.
authors.forename: John P
authors.initials: JP
authors.lastname: Leonard
authors.affiliation: Rush Medical Center, Chicago, IL.
authors.forename: Stephanie A
authors.initials: SA
authors.lastname: Gregory
authors.affiliation: Tufts New England Medical Center, Boston, MA.
authors.forename: Hedy
authors.initials: H
authors.lastname: Smith
authors.affiliation: GlaxoSmithKline, Collegeville, PA.
authors.forename: Thierry J
authors.initials: TJ
authors.lastname: Horner
authors.affiliation: GlaxoSmithKline, Research Triangle Park, NC.
authors.forename: Vanessa C
authors.initials: VC
authors.lastname: Williams
authors.affiliation: GlaxoSmithKline, Collegeville, PA.
authors.forename: Patricia
authors.initials: P
authors.lastname: Giampietro
authors.affiliation: GlaxoSmithKline, Collegeville, PA. Electronic address: tlin23@its.jnj.com.
authors.forename: Thomas S
authors.initials: TS
authors.lastname: Lin
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000627:therapeutic use; D018572:Disease-Free Survival; D004317:Doxorubicin / Q000627:therapeutic use; D005260:Female; D006801:Humans; D016403:Lymphoma, Large B-Cell, Diffuse / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011241:Prednisone / Q000627:therapeutic use; D016896:Treatment Outcome; D014750:Vincristine / Q000627:therapeutic use; D055815:Young Adult
chemical_list: D000911:Antibodies, Monoclonal; D014750:Vincristine; D004317:Doxorubicin; D003520:Cyclophosphamide; C119496:tositumomab I-131; D011241:Prednisone
keywords: Bexxar; Consolidation therapy; DLBCL; Radioimmunotherapy